Hot Picks

AI-vetted picks: crashed companies whose fundamentals still hold up.

Earlier picks 3

Everything the screener has flagged before, most recent first.

LULU

⚠ TRAP detected 2026-10-01 Fundamentals57/100

✗Avoid: Avoid — this is a multi-year structural slowdown (US sales shrinking, tariffs, lost CEO, rising competition), not a temporary panic.

Declined -81.2% from its all-time high of $511.29 — now $96.19

I bought this

Full analysis & scorecard›

What's going on

LULU has fallen for two straight years on a steady drumbeat of bad news: tariffs cutting margins, North American/US sales now actually shrinking (down 8% most recently), intensifying competition from Vuori/Alo, customer complaints about product quality, and a leadership vacuum after CEO Calvin McDonald's exit with no permanent replacement plus governance fights with founder Chip Wilson.

The case for it

The low P/E and strong margins look tempting, but they reflect last year's business, not this year's. Every recent quarter has brought a further guidance cut, confirming the US (the company's profit engine) is still deteriorating with no stabilization in sight, and management itself says a real fix is at least a year away.

What could go wrong

If a strong permanent CEO is hired and the 'product reset' works internationally and in the US, the stock could re-rate — but every single quarter so far has brought disappointment, not improvement, so betting on a turnaround today is catching a falling knife.

Fwd P/E 11.2Op margin 13.2%Rev growth -4.3%Debt/equity 44.7%Analyst upside 8.6%

How this scored 57/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 12.8%

✅ Generates cash Free cash flow $1.1B

✅ Not drowning in debt Debt/equity 44.7% (limit 200%)

✅ Can pay its bills Current ratio 2.2 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 18/25

Operating margin 13.2% 5/9

Net profit margin 12.8% 5/8

Return on equity 30.9% 8/8

Growth Is it getting bigger, or dying? 1/25

Revenue growth -4.3% 0/9

Earnings growth -5.9% 1/8

Expected profit change -28.3% 0/8

Value Is it cheap right now? 16/25

Forward P/E 11.2 9/10

PEG ratio 1.1 6/8

Analyst target upside 8.6% 1/7

Balance sheet Will it survive? 22/25

Debt / equity 44.7% 9/10

Current ratio 2.2 6/8

Free cash flow $1.1B 7/7

source · source · source · source · source

PATH

⚠ TRAP detected 2026-10-01 Fundamentals81/100

✗Avoid: Avoid — cheap because the market thinks AI agents (from Microsoft, OpenAI, Salesforce) are making UiPath's core product obsolete, not because of a one-off scare.

Declined -83.9% from its all-time high of $79.82 — now $12.84

I bought this

Full analysis & scorecard›

What's going on

The stock has been in a near-continuous five-year downtrend since 2021 driven by fear that generative AI and AI agents let companies automate tasks themselves without needing UiPath's software; the latest leg down came from weak fiscal guidance, slowing revenue growth, and a fresh analyst downgrade over customers resisting UiPath's new AI pricing model.

The case for it

Bulls would say UiPath is now genuinely profitable, debt-free, generating strong free cash flow, and trades cheaply at a forward P/E near 14 — if it can prove its "agentic" AI platform is additive rather than replaceable, the stock could re-rate higher. But that is exactly the unresolved question the market is punishing it for, not a case of panic over nothing.

What could go wrong

This is a textbook "slow bleed" pattern: multiple separate 20%+ drops since 2021, most of which kept falling further over the next year, and each new rally has been sold as competitors (Microsoft Power Automate, Salesforce, and now OpenAI's enterprise agent products) chip away at the reason to use a standalone RPA vendor at all — revenue growth has already decelerated to the low-to-mid teens and guidance keeps disappointing.

Fwd P/E 14.3Op margin 8.9%Rev growth 13.4%Debt/equity 4.1%Analyst upside 17.6%

How this scored 81/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 21.0%

✅ Generates cash Free cash flow $474M

✅ Not drowning in debt Debt/equity 4.1% (limit 200%)

✅ Can pay its bills Current ratio 2.4 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 17/25

Operating margin 8.9% 3/9

Net profit margin 21.0% 8/8

Return on equity 20.0% 6/8

Growth Is it getting bigger, or dying? 22/25

Revenue growth 13.4% 6/9

Earnings growth 2280.8% 8/8

Expected profit change 37.5% 8/8

Value Is it cheap right now? 18/25

Forward P/E 14.3 8/10

PEG ratio 0.5 8/8

Analyst target upside 17.6% 2/7

Balance sheet Will it survive? 24/25

Debt / equity 4.1% 10/10

Current ratio 2.4 7/8

Free cash flow $474M 7/7

source · source · source · source · source

ALGN

⚠ TRAP detected 2026-10-01 Fundamentals64/100

✗Avoid: Avoid — Invisalign demand growth has stalled for years with earnings now shrinking, and cheap valuation reflects a genuinely slower, more competitive business, not a market overreaction.

Declined -80.0% from its all-time high of $725.24 — now $145.35

I bought this

Full analysis & scorecard›

What's going on

Align Technology's stock never recovered from its 2021 peak because the pandemic-era boom in clear aligners (driven by stuck-at-home teens/adults and easy credit) normalized, and growth has settled into low-single digits (4.3% revenue growth here) with earnings now declining (-12.1%) amid rising competition, softer discretionary spending on elective dental work, and uneven international (especially China) demand — not a one-time event but a multi-year structural deceleration.

The case for it

Bulls would point to a strong balance sheet (almost no debt, $1.1B cash, healthy free cash flow) and a low forward P/E (11.6) with a PEG under 1, suggesting the market is pricing in more pessimism than the numbers justify. If Invisalign volumes stabilize or reaccelerate internationally, the stock could re-rate higher from today's depressed multiple.

What could go wrong

The core problem is growth, not valuation: revenue growth of 4.3% and shrinking earnings (-12.1%) show the business is not just cheap, it's decelerating, and margins (18% operating, 10% net) are well below the company's pre-2021 highs, meaning the 'cheap' forward P/E assumes an earnings rebound that hasn't shown up yet — a classic case of a statistically cheap stock that stays cheap because the growth story that justified its old premium multiple is permanently gone.

Fwd P/E 11.6Op margin 18.2%Rev growth 4.3%Debt/equity 2.9%Analyst upside 42.0%

How this scored 64/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 10.0%

✅ Generates cash Free cash flow $594M

✅ Not drowning in debt Debt/equity 2.9% (limit 200%)

✅ Can pay its bills Current ratio 1.4 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 13/25

Operating margin 18.2% 7/9

Net profit margin 10.0% 4/8

Return on equity 10.2% 2/8

Growth Is it getting bigger, or dying? 11/25

Revenue growth 4.3% 3/9

Earnings growth -12.1% 0/8

Expected profit change 117.1% 8/8

Value Is it cheap right now? 21/25

Forward P/E 11.6 9/10

PEG ratio 0.6 8/8

Analyst target upside 42.0% 5/7

Balance sheet Will it survive? 19/25

Debt / equity 2.9% 10/10

Current ratio 1.4 2/8

Free cash flow $594M 7/7

🔒

31 more picks — AI-vetted, waiting for you

The Free plan shows 3 picks. Upgrade to Pro to see every pick, the full screener, insider trades, portfolio tracking and Telegram alerts.

Unlock all picks — $29/mo